M. Roelvink

931 total citations
16 papers, 737 citations indexed

About

M. Roelvink is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, M. Roelvink has authored 16 papers receiving a total of 737 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 8 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in M. Roelvink's work include Cancer therapeutics and mechanisms (5 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Treatments and Mutations (4 papers). M. Roelvink is often cited by papers focused on Cancer therapeutics and mechanisms (5 papers), Lung Cancer Research Studies (5 papers) and Lung Cancer Treatments and Mutations (4 papers). M. Roelvink collaborates with scholars based in United Kingdom, Netherlands and Germany. M. Roelvink's co-authors include Herbert M. Pinedo, Yukio Ando, Hans van Vliet, Marlies Peters, Cornelis J. A. Punt, Jos H. Beijnen, Alfons J.M. van den Eertwegh, Giuseppe Giaccone, Rik J. Scheper and Rita Ruijter and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

M. Roelvink

16 papers receiving 720 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
M. Roelvink United Kingdom 10 410 397 225 44 42 16 737
Brian J. Czerniecki United States 12 413 1.0× 342 0.9× 180 0.8× 15 0.3× 27 0.6× 23 615
Evelien W. Duiker Netherlands 14 291 0.7× 345 0.9× 332 1.5× 108 2.5× 48 1.1× 26 750
Nectaria N. Sotiriadou Greece 13 438 1.1× 375 0.9× 169 0.8× 9 0.2× 22 0.5× 15 655
Jennifer S. Childs United States 14 581 1.4× 529 1.3× 232 1.0× 29 0.7× 35 0.8× 46 812
John B. Beard United States 7 168 0.4× 110 0.3× 302 1.3× 106 2.4× 18 0.4× 8 513
M.R. Price United Kingdom 15 132 0.3× 118 0.3× 294 1.3× 27 0.6× 21 0.5× 29 502
Florian J. Groelly United Kingdom 6 250 0.6× 398 1.0× 599 2.7× 20 0.5× 37 0.9× 7 893
J. J. Mahany United States 9 487 1.2× 541 1.4× 205 0.9× 6 0.1× 39 0.9× 22 766
Peter Maimonis United States 11 159 0.4× 294 0.7× 331 1.5× 8 0.2× 16 0.4× 19 599
Wendie Hopkins Australia 15 503 1.2× 326 0.8× 322 1.4× 6 0.1× 21 0.5× 22 764

Countries citing papers authored by M. Roelvink

Since Specialization
Citations

This map shows the geographic impact of M. Roelvink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Roelvink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Roelvink more than expected).

Fields of papers citing papers by M. Roelvink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Roelvink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Roelvink. The network helps show where M. Roelvink may publish in the future.

Co-authorship network of co-authors of M. Roelvink

This figure shows the co-authorship network connecting the top 25 collaborators of M. Roelvink. A scholar is included among the top collaborators of M. Roelvink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Roelvink. M. Roelvink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Glen, Hilary, R.S. Morrison, M. Roelvink, et al.. (2008). A phase I study of E7080 in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 26(15_suppl). 3526–3526. 7 indexed citations
2.
Langenberg, Marlies H.G., Henk M.W. Verheul, Jeanine M.L. Roodhart, et al.. (2008). Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. Journal of Clinical Oncology. 26(15_suppl). 2530–2530. 1 indexed citations
3.
Fong, Peter C.C., David S. Boss, C. P. Carden, et al.. (2008). AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Journal of Clinical Oncology. 26(15_suppl). 5510–5510. 65 indexed citations
4.
Glen, Hilary, David S. Boss, T. R. J. Evans, et al.. (2007). A phase I dose finding study of E7080 in patients (pts) with advanced malignancies. Journal of Clinical Oncology. 25(18_suppl). 14073–14073. 7 indexed citations
5.
6.
Bono, Johann S. de, Peter C.C. Fong, David S. Boss, et al.. (2006). 503 POSTER Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evalutation of an oral small molecule inhibitor of Poly ADP-Ribose Polymerase (PARP), Ku in patients (p) with advance tumours. European Journal of Cancer Supplements. 4(12). 153–153. 2 indexed citations
7.
Schrijvers, D., Elisabeth G.E. de Vries, J. Wanders, et al.. (2002). Phase I study of MEN-10755, a new anthracycline in patients with solid tumours: a report from the European Organization for Research and Treatment of Cancer, Early Clinical Studies Group. Annals of Oncology. 13(3). 385–391. 11 indexed citations
8.
Schellens, Jan H.M., Bernhard Heinrich, M. Lehnert, et al.. (2002). Population Pharmacokinetic and Dynamic Analysis of the Topoisomerase I Inhibitor Lurtotecan in Phase II Studies. Investigational New Drugs. 20(1). 83–93. 10 indexed citations
9.
Giaccone, Giuseppe, Cornelis J. A. Punt, Yukio Ando, et al.. (2002). A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.. PubMed. 8(12). 3702–9. 426 indexed citations
10.
11.
Bos, Arend F., Elisabeth G.E. de Vries, Steinar Aamdal, et al.. (2001). Pharmacokinetics of MEN-10755, a novel anthracycline disaccharide analogue, in two phase I studies in adults with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 48(5). 361–369. 11 indexed citations
12.
Gamucci, Teresa, Bernhard Heinrich, Jan H.M. Schellens, et al.. (2000). Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC—ECSG phase II clinical study. Annals of Oncology. 11(7). 793–797. 20 indexed citations
13.
Sessa, Cristiana, J. Wanders, M. Roelvink, et al.. (2000). Second-line treatment of small-cell lung cancer with the camptothecin-derivative GI147211: A study of the EORTC Early Clinical Studies Group (ECSG). Annals of Oncology. 11(2). 207–210. 16 indexed citations
14.
Roelvink, M., J. Wanders, A.-R. Hanauske, et al.. (1999). Phase I pharmacokinetic study of MEN-10755 in solid tumors. European Journal of Cancer. 35. S291–S291. 1 indexed citations
15.
Roelvink, M., P Dombernowsky, J. Wanders, et al.. (1999). A Phase I study of men-10755 in patients with a solid tumor as a shorti.v. infusion given once every 3 weeks. European Journal of Cancer. 35. S289–S289. 5 indexed citations
16.
Judson, Ian, T. Cerny, Ron Epelbaum, et al.. (1997). Phase II trial of the oral platinum complex JM216 in non-small-cell lung cancer: An EORTC early clinical studies group investigation. Annals of Oncology. 8(6). 604–606. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian J. Czerniecki Breakdown of academic impact, for papers by Evelien W. Duiker Breakdown of academic impact, for papers by Nectaria N. Sotiriadou Breakdown of academic impact, for papers by Jennifer S. Childs Breakdown of academic impact, for papers by John B. Beard Breakdown of academic impact, for papers by M.R. Price Breakdown of academic impact, for papers by Florian J. Groelly Breakdown of academic impact, for papers by J. J. Mahany Breakdown of academic impact, for papers by Peter Maimonis Breakdown of academic impact, for papers by Wendie Hopkins
Rankless by CCL
2026